Johnson & Johnson $JNJ Shares Bought by Graham Capital Management L.P.

Key Points

• Graham Capital Management L.P. increased its stake in Johnson & Johnson by 2.9%, acquiring an additional 3,230 shares during the first quarter, resulting in a total ownership of 114,555 shares.
• Johnson & Johnson reported a 25% net margin and $23.74 billion in revenue for the last quarter, exceeding analyst expectations.
• The company announced a quarterly dividend of $1.30 per share, reflecting a 2.9% yield, set to be paid on September 9th.

Graham Capital Management L.P. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 2.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 114,555 shares of the company's stock after acquiring an additional 3,230 shares during the quarter. Johnson & Johnson accounts for about 0.3% of Graham Capital Management L.P.'s holdings, making the stock its 23rd largest position. Graham Capital Management L.P.'s holdings in Johnson & Johnson were worth $18,998,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the company. Highline Wealth Partners LLC lifted its holdings in Johnson & Johnson by 51.8% during the 1st quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after purchasing an additional 86 shares in the last quarter. Stone House Investment Management LLC purchased a new position in Johnson & Johnson during the 1st quarter valued at about $47,000. von Borstel & Associates Inc. purchased a new position in Johnson & Johnson during the 1st quarter valued at about $49,000. Capital A Wealth Management LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $50,000. Finally, Harvest Fund Management Co. Ltd purchased a new position in Johnson & Johnson during the first quarter valued at approximately $52,000. 69.55% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on JNJ shares. Wall Street Zen cut shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a research note on Friday, July 18th. Morgan Stanley boosted their target price on Johnson & Johnson from $171.00 to $176.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 17th. Erste Group Bank raised Johnson & Johnson from a "hold" rating to a "buy" rating in a research note on Wednesday, July 23rd. Piper Sandler reissued an "overweight" rating on shares of Johnson & Johnson in a research note on Thursday, July 17th. Finally, UBS Group boosted their target price on Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a research note on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $176.29.

Johnson & Johnson Trading Up 0.4%

NYSE:JNJ traded up $0.64 during trading hours on Tuesday, reaching $177.81. 9,032,088 shares of the company were exchanged, compared to its average volume of 7,666,583. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76. The firm has a market cap of $428.23 billion, a price-to-earnings ratio of 19.02, a PEG ratio of 2.26 and a beta of 0.40. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $181.16. The stock has a 50 day simple moving average of $166.51 and a 200 day simple moving average of $160.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter last year, the firm posted $2.82 EPS. The business's revenue for the quarter was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be given a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is currently 55.61%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.